Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

Fig. 2

Median LQI selected item scores (range: 0–8) from combined analysis of data from the North American and European studies from pre-Ig20Gly period to end of study for Ig20Gly therapy by prior treatment setting, age group, prior route of administration, and study location. Ig20Gly, immune globulin subcutaneous (human) 20%; IVIG, intravenous immunoglobulin; LQI, Life Quality Index; SCIG, subcutaneous immunoglobulin. Note: Bar charts indicate the median score and interquartile range (error bars) for each sample or subgroup in the pre-Ig20Gly period and at the end of the study. The median ∆ value is the median within-patient difference in scores between the end of the pre-Ig20Gly period and the end of the study. P values indicate statistical significance for differences in distributions of scores between the pre-Ig20Gly period and the end of the study assessed using the Wilcoxon signed-rank test

Back to article page